Maccura Biotechnology Co.Ltd (300463.SZ)
CNY 12.06
(0.08%)
CNY 12.06
(0.08%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 175.47 Million CNY | -41.67% |
| 2022 | 300.83 Million CNY | -31.82% |
| 2021 | 441.25 Million CNY | 33.83% |
| 2020 | 329.7 Million CNY | 64.85% |
| 2019 | 200 Million CNY | -20.0% |
| 2018 | 250 Million CNY | 108.33% |
| 2017 | 120 Million CNY | 0.0% |
| 2016 | - CNY | -100.0% |
| 2015 | 69 Million CNY | -45.67% |
| 2014 | 127 Million CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 112 Million CNY | -31.08% |
| 2024 Q3 | 142.64 Million CNY | -1.38% |
| 2024 Q2 | 144.64 Million CNY | 29.14% |
| 2023 Q4 | 175.47 Million CNY | -19.19% |
| 2023 Q3 | 217.13 Million CNY | -50.54% |
| 2023 Q1 | 349.5 Million CNY | 16.18% |
| 2023 FY | 175.47 Million CNY | -41.67% |
| 2023 Q2 | 439.03 Million CNY | 25.62% |
| 2022 Q4 | 300.83 Million CNY | -14.18% |
| 2022 Q3 | 350.53 Million CNY | -0.74% |
| 2022 Q2 | 353.13 Million CNY | 1.29% |
| 2022 FY | 300.83 Million CNY | -31.82% |
| 2022 Q1 | 348.62 Million CNY | -20.99% |
| 2021 FY | 441.25 Million CNY | 33.83% |
| 2021 Q4 | 441.25 Million CNY | 9.28% |
| 2021 Q1 | 252.57 Million CNY | -23.39% |
| 2021 Q2 | 252.07 Million CNY | -0.2% |
| 2021 Q3 | 403.76 Million CNY | 60.18% |
| 2020 Q4 | 329.7 Million CNY | -17.55% |
| 2020 FY | 329.7 Million CNY | 64.85% |
| 2020 Q2 | 349.9 Million CNY | -10.28% |
| 2020 Q1 | 390 Million CNY | 95.0% |
| 2020 Q3 | 399.9 Million CNY | 14.29% |
| 2019 Q4 | 200 Million CNY | 17.65% |
| 2019 Q3 | 170 Million CNY | -32.0% |
| 2019 Q2 | 250 Million CNY | 0.0% |
| 2019 Q1 | 250 Million CNY | 0.0% |
| 2019 FY | 200 Million CNY | -20.0% |
| 2018 FY | 250 Million CNY | 108.33% |
| 2018 Q2 | 250 Million CNY | 66.67% |
| 2018 Q1 | 150 Million CNY | 25.0% |
| 2018 Q4 | 250 Million CNY | 0.0% |
| 2018 Q3 | 250 Million CNY | 0.0% |
| 2017 Q1 | - CNY | 0.0% |
| 2017 FY | 120 Million CNY | 0.0% |
| 2017 Q4 | 120 Million CNY | 0.0% |
| 2017 Q3 | - CNY | -100.0% |
| 2017 Q2 | - CNY | 0.0% |
| 2016 FY | - CNY | -100.0% |
| 2016 Q4 | - CNY | -100.0% |
| 2016 Q3 | 29 Million CNY | 0.0% |
| 2016 Q2 | 29 Million CNY | -57.97% |
| 2016 Q1 | 69 Million CNY | 0.0% |
| 2015 Q1 | 127 Million CNY | 0.0% |
| 2015 FY | 69 Million CNY | -45.67% |
| 2015 Q4 | 69 Million CNY | -47.73% |
| 2015 Q3 | 132 Million CNY | 0.0% |
| 2015 Q2 | 132 Million CNY | 3.94% |
| 2014 FY | 127 Million CNY | 0.0% |
| 2014 Q4 | 127 Million CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 2.33 Billion CNY | 92.469% |
| Hangzhou Tigermed Consulting Co., Ltd. | 434.22 Million CNY | 59.588% |
| Dirui Industrial Co.,Ltd. | 3.66 Million CNY | -4685.319% |
| Beijing Strong Biotechnologies, Inc. | 1.13 Billion CNY | 84.494% |
| Medicalsystem Biotechnology Co., Ltd. | 23.59 Million CNY | -643.678% |
| Guangzhou Wondfo Biotech Co.,Ltd | 580.52 Million CNY | 69.773% |
| Guangdong Hybribio Biotech Co.,Ltd. | 28.26 Million CNY | -520.755% |
| BGI Genomics Co., Ltd. | 283.42 Million CNY | 38.087% |
| Amoy Diagnostics Co., Ltd. | 44.4 Million CNY | -295.221% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 166.83 Million CNY | -5.179% |